---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Generic, brand name and therapeutic class of product"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Generic, brand name and therapeutic class of product. Topics: Manufacturer: Rezolute; Commercial manufacturing by third parties; Licensor: XOMA, acquired by Ligand Pharmaceuticals in July 2026; International nonproprietary name; 2 further topics. 6 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/generic-brand-name-and-therapeutic-class-of-product"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Generic, brand name and therapeutic class of product

<a id="heading-2.1.2.1"></a>

## 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

### Manufacturer: Rezolute

> “Sponsor: Rezolute Inc.”

Source: [FDA Orphan Drug Designations and Approvals (2024)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=966723)

> “Our lead clinical asset, ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

> “The Company’s antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-2.1.2.1-2"></a>

### Commercial manufacturing by third parties

> “We also expect to rely upon third parties to produce materials required for the commercial production of our product candidates if we succeed in obtaining necessary regulatory approvals.”
> “We rely upon a small number of third-party suppliers for the manufacture of certain raw materials that are necessary to formulate our drug products for preclinical and clinical testing purposes.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="topic-2.1.2.1-3"></a>

### Licensor: XOMA, acquired by Ligand Pharmaceuticals in July 2026

> “pursuant to which XOMA granted an exclusive global license to the Company to develop and commercialize ersodetug for all indications.”
> “On July 14, 2026, XOMA was acquired by Ligand Pharmaceuticals Incorporated”
> “The next milestone payment of $25.0 million will be due upon regulatory approval for ersodetug by any regulatory authority.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="topic-2.1.2.1-4"></a>

### International nonproprietary name

> “ersodetug immunoglobulin G2-kappa, anti-[Homo sapiens INSR (insulin receptor)], Homo sapiens monoclonal antibody, allosteric”

Source: [WHO INN Proposed List 128 (2022)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl128.pdf)

<a id="topic-2.1.2.1-5"></a>

### Development codes and former names: XOMA 358 and RZ358

> “On 14 July 2016, orphan designation (EU/3/16/1702) was granted by the European Commission to XOMA UK Limited, United Kingdom, for the recombinant human monoclonal antibody to insulin receptor (also known as XOMA 358) for the treatment of congenital hyperinsulinism.”
> “The sponsorship was transferred to Rezolute (Bio) Ireland Limited, Ireland in June 2022”

Source: [EMA congenital hyperinsulinism orphan designation (2016)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1702)

> “XOMA 358 (X358) is a fully human monoclonal antibody to the insulin receptor that acts as a negative allosteric modulator of insulin signaling.”

Source: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

> “today announced that it received U.S. Food and Drug Administration (FDA) clearance for its Investigational New Drug (IND) application for RZ358 (ersodetug) to treat hypoglycemia in patients with tumor hyperinsulinism (HI).”

Source: [Rezolute tumor HI IND clearance release (2024)](https://ir.rezolutebio.com/news/detail/337/rezolute-announces-fda-clearance-of-ind-application-for-phase-3-registrational-study-of-rz358-for-treatment-of-hypoglycemia-due-to-tumor-hyperinsulinism)

<a id="topic-2.1.2.1-6"></a>

### Brand name

No evidence found.

<a id="topic-2.1.2.1-7"></a>

### Therapeutic class: fully human monoclonal antibody, allosteric insulin receptor modulator

> “immunoglobulin G2-kappa, anti-[Homo sapiens INSR (insulin receptor)], Homo sapiens monoclonal antibody, allosteric”
> “produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1, glycoform alfa”

Source: [WHO INN Proposed List 128 (2022)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl128.pdf)

> “Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances (such as IGF-2) in the setting of hyperinsulinism (HI), thereby improving hypoglycemia.”
> “Ersodetug for the treatment of HI is investigational.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
